#PMVP hashtag - Bluesky

3 weeks ago

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights PMV Pharmaceuticals (Nasdaq: PMVP) reported full-year 2025 results and clinical progress for rezatapopt. Key clinical highlights include FDA Orphan Drug Designation (Mar 2, 2026), NEJM publication of Phase 1 data, Phase 2 PYNNACLE activity with ovarian cohort ORRs up to 50% post-cutoff, and an NDA planned for Q1 2027. Financials: $112.9M cash and marketable securities as of Dec 31, 2025, net loss of $77.7M, and net cash used in operations of $73.6M, providing runway to end of Q2 2027.

#PMVP PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

www.stocktitan.net/news/PMVP/pmv-pharmaceut...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors PMV Pharma (Nasdaq: PMVP) reported that Phase 1, first-in-human rezatapopt data were published in the New England Journal of Medicine on Feb 26, 2026. The Phase 1 portion enrolled 77 heavily pretreated TP53 Y220C-mutant patients, showed objective responses across tumor types, supported an RP2D, and demonstrated safety, pharmacokinetics, and biomarker evidence of selective Y220C p53 reactivation. The company plans a New Drug Application submission in Q1 2027 for platinum-resistant/refractory ovarian cancer and reported Phase 2 interim ORR of 34% overall and 46% in ovarian cancer (data cutoff Sep 4, 2025).

#PMVP New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

www.stocktitan.net/news/PMVP/new-england-jo...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

#PMVP PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights

www.stocktitan.net/news/PMVP/pmv-pharmaceut...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PMV Pharmaceuticals (Nasdaq: PMVP) reported updated Phase 2 PYNNACLE monotherapy data for rezatapopt (TP53 Y220C) with a 34% ORR across 103 evaluable patients and median duration of response of 7.6 months (data cutoff Sept 4, 2025). Confirmed responses appeared in eight tumor types including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary cancer.The ovarian cohort showed a 46% ORR (22/48) with median duration of response 8.0 months. Safety was mostly Grade 1–2; Grade 3 TRAEs ≤6% and drug discontinuations due to TRAEs were 3.6%. An NDA for platinum-resistant/refractory ovarian cancer is planned for Q1 2027.

#PMVP PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

www.stocktitan.net/news/PMVP/pmv-pharmaceut...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PMV Pharmaceuticals (NASDAQ:PMVP) announced promising interim data from its Phase 2 PYNNACLE trial evaluating rezatapopt in patients with TP53 Y220C-mutated advanced solid tumors. The trial demonstrated a 33% overall response rate (ORR) across 97 evaluable patients, with confirmed responses in eight different tumor types.Key highlights include a 43% ORR in ovarian cancer patients with 7.6 months median duration of response. The safety profile showed mostly Grade 1-2 treatment-related adverse events, with a low 3.7% discontinuation rate. Following FDA feedback, PMV plans to enroll an additional 20-25 platinum resistant/refractory ovarian cancer patients and submit a New Drug Application (NDA) in Q1 2027.

#PMVP PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

www.stocktitan.net/news/PMVP/pmv-pharmaceut...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, has announced its Q2 2025 financial results and will host an investor webinar on September 10, 2025 to review interim analysis data from the Phase 2 PYNNACLE clinical trial. The analysis will include data from approximately 65 patients with at least 18 weeks of follow-up, with about 45% in the ovarian cancer cohort.The company reported $148.3 million in cash and equivalents as of June 30, 2025, providing runway through 2026. Q2 2025 net loss was $21.2 million, compared to $1.2 million in Q2 2024. R&D expenses increased to $18.4 million, while G&A expenses decreased to $4.5 million.

#PMVP PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

www.stocktitan.net/news/PMVP/pmv-pharmaceut...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights PMV Pharmaceuticals (PMVP) has reported its Q1 2025 financial results and provided updates on its PYNNACLE clinical trial for rezatapopt. The company plans to release interim analysis data from approximately 50 patients in mid-2025, with 40% from the ovarian cancer cohort. Financially, PMV ended Q1 with $165.8 million in cash and equivalents, expecting runway through 2026.The company reported a net loss of $17.5 million for Q1 2025, compared to $15.3 million in Q1 2024. R&D expenses increased to $17.4 million from $13.2 million year-over-year, while G&A expenses decreased to $4.1 million from $5.0 million. Net cash used in operations was $18.3 million for Q1 2025.

#PMVP PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights

www.stocktitan.net/news/PMVP/pmv-pharmaceut...